Catalog No.
Product Name
Application
Product Information
Citations
-
Lactate Dehydrogenase Inhibitor
LDHA-IN-5 is a potent inhibitor of lactate dehydrogenase (LDHA), targeting its enzymatic activity to modulate metabolic pathways. This compound exhibits significant potential in research applications related to metabolic disorders, including primary hyperoxaluria. By inhibiting LDHA, LDHA-IN-5 may help to reduce lactate levels and influence cellular metabolism, making it a valuable tool for understanding disease mechanisms and developing therapeutic strategies. -
PCSK9 Inhibitor
MeIm is a potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) that acts as a peptide mimetic. It effectively enhances the cellular uptake of low-density lipoprotein (LDL) with an EC50 value of 6.04 μM by disrupting the interaction between PCSK9 and LDL receptors (LDLR), with an IC50 of 11.2 μM. MeIm is valuable for research focused on cardiovascular diseases and related lipid metabolism studies. -
PCSK9 Inhibitor
BRD8518 is a potent inhibitor of PCSK9, exhibiting an EC50 of 0.23 μM. By upregulating LDLR expression, BRD8518 effectively lowers blood lipid levels and enhances LDL uptake. This compound is valuable for research applications focused on cardiovascular diseases, facilitating the exploration of lipid metabolism and associated therapeutic strategies. -
LXR Antagonist
PFM046 is a potent antagonist of the liver X receptors (LXRα and LXRβ), demonstrating IC50 values of 2.04 μM and 1.58 μM, respectively. This compound effectively inhibits the expression of stearoyl-CoA desaturase 1 (SCD1) and fatty acid synthase (FASN), while promoting the expression of ATP-binding cassette transporter A1 (ABCA1). PFM046 has shown promising antitumor efficacy in preclinical mouse models, making it a valuable tool for research in cancer therapeutics and lipid metabolism pathways. -
SREBP Maturation Inhibitor
4'-Hydroxyflavanone is an inhibitor of SREBP maturation, impacting lipid synthesis. As a synthetic analogue of flavanone, it demonstrates potential in studies related to hepatic steatosis and dyslipidemia. This compound can be utilized to explore mechanisms of lipid metabolism and associated disorders. -
SREBP/SCAP Inhibitor
SREBP/SCAP-IN-1 is a selective inhibitor of the SREBP/SCAP complex, which plays a crucial role in lipid metabolism and cellular cholesterol homeostasis. This compound effectively disrupts the signaling pathway involved in sterol regulatory element-binding protein activation, providing insight into lipid regulation mechanisms. Research applications include investigating metabolic disorders, cardiovascular diseases, and potential therapeutic strategies targeting cholesterol metabolism. -
SREBP/SCAP Inhibitor
SREBP/SCAP-IN-2 is a selective inhibitor of the SREBP/SCAP complex, which plays a crucial role in lipid metabolism and cellular cholesterol homeostasis. This compound effectively interferes with the activation and function of SREBP, thereby modulating lipid biosynthesis pathways. SREBP/SCAP-IN-2 is valuable for research focusing on metabolic disorders, obesity, and cardiovascular diseases, providing insights into the regulatory mechanisms of lipid metabolism. -
FXR agonist
Deoxycholic acid 3-O-β-D-glucuronide disodium is a potent agonist of the farnesoid X receptor (FXR). This compound has been shown to play a significant role in regulating bile acid homeostasis, lipid metabolism, and glucose metabolism. Its applications include the study of metabolic disorders, liver diseases, and potential therapeutic strategies targeting FXR signaling pathways. -
FXR Antagonist
Tauro-β-muricholic acid sodium is a competitive and reversible antagonist of the farnesoid X receptor (FXR), exhibiting an IC50 of 40 μM. This compound plays a significant role in the modulation of bile acid signaling and is utilized in research applications related to metabolic diseases, liver function, and cholesterol homeostasis. Its ability to inhibit FXR makes it a valuable tool for studying the physiological and pathological roles of bile acids in various biological systems. -
FXR Agonist
FXR Agonist 3 is a potent farnesoid X receptor (FXR) agonist, designed for the treatment of non-alcoholic steatohepatitis (NASH). This compound effectively inhibits the expression of COL1A1, TGF-β1, α-SMA, and TIMP1, showcasing significant anti-fibrogenic properties. Additionally, FXR Agonist 3 markedly reduces liver steatosis and inflammation while improving levels of liver fibrosis, making it a valuable tool in liver disease research. -
FXR Agonist
Arjungenin is a pentacyclic triterpenoid that serves as a potent agoinist of the farnesoid X receptor (FXR). It enhances insulin sensitivity by modulating the functionality of adipocytes, making it relevant for metabolic research. In addition, Arjungenin demonstrates moderate free radical scavenging activity and exhibits inhibitory effects on the growth of Spilarctia obliqua larvae. Its antiviral properties include significant activity against various viruses, notably chikungunya virus (CHIKV). -
FXR Activators
Chenodeoxycholic acid 3-glucuronide is an active metabolite of Chenodeoxycholic acid that serves as a selective Farnesoid X receptor (FXR) activator, exhibiting an EC50 of 8 μM in in vitro assays. This compound effectively modulates FXR signaling pathways, which are crucial for bile acid homeostasis and lipid metabolism. Research applications include studying metabolic disorders, liver physiology, and the potential therapeutic effects of FXR activation in various disease models. -
FXR Antagonist
FXR Antagonist 1 is a selective antagonist of the farnesoid X receptor (FXR) with an IC50 of 2.1 μM. This compound effectively inhibits intestinal FXR signaling, promoting feedback activation of hepatic FXR. Its primary biological activity involves ameliorating hepatic steatosis, inflammation, and fibrosis in models of nonalcoholic steatohepatitis (NASH). FXR Antagonist 1 is a valuable tool for research focused on NASH and related metabolic disorders. -
FXR Agonist
Omesdafexor is a potent FXR agonist characterized by its unique non-bile acid structure, demonstrating efficacy in modulating bile acid and lipid metabolism. This compound is particularly relevant for research in non-alcoholic steatohepatitis (NASH), offering insights into therapeutic strategies for metabolic liver diseases. Its oral bioactivity facilitates its application in in vivo studies, making it a valuable tool for investigating FXR-related pathways in liver health and disease. -
FXR Activator
Linafexor is a potent FXR ( Farnesoid X Receptor) agonist that modulates bile acid homeostasis. By activating FXR, it plays a crucial role in regulating liver function. This compound is particularly relevant for research on primary sclerosing cholangitis (PSC) and metabolic dysfunction-associated steatohepatitis (MASH), offering insights into therapeutic strategies for liver-related diseases. -
FXR/FABP1 Dual Modulator
ZLY28 is a first-in-class dual modulator targeting farnesoid X receptor (FXR) and fatty acid-binding protein 1 (FABP1). This orally active compound exhibits significant potential as an anti-NASH agent, making it a valuable tool for research into nonalcoholic steatohepatitis (NASH) and related metabolic conditions. Its intestinal-restricted activity highlights its specificity, providing an innovative approach to studying lipid metabolism and liver function. -
FXR Antagonist
V023-9340 is a potent antagonist of the farnesoid X receptor (FXR), exhibiting an IC50 of 4.27 μM. This compound is a valuable tool for investigating the role of FXR in the pathology of nonalcoholic steatohepatitis (NASH) and other related metabolic disorders. Its inhibitory action allows for the exploration of FXR's involvement in lipid metabolism and inflammation pathways, making it useful in therapeutic research targeting these conditions. -
FXR Agonist
Glyco-Obeticholic acid is an active metabolite of Obeticholic acid and acts as a farnesoid X receptor (FXR) agonist. By activating FXR, it plays a vital role in regulating bile acid homeostasis, lipid metabolism, and glucose metabolism. This compound is primarily used in research to investigate metabolic disorders, liver diseases, and potential therapeutic strategies for cholestatic liver conditions. -
FXR Agonist
FXR Agonist 5 functions as a selective agonist for the farnesoid X receptor (FXR). This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research on metabolic disorders characterized by inflammation. Its application extends to studying the role of FXR in regulating bile acid homeostasis and glucose metabolism, thus providing insights into potential therapeutic strategies for related diseases. -
FXRα Antagonist
NDB is a selective antagonist of the human farnesoid X receptor alpha (hFXRα), serving to modulate the transcription of downstream genes associated with this pathway. This compound demonstrates potential in anti-diabetic research by influencing metabolic processes regulated by FXRα. Its application is particularly relevant for studies investigating the role of bile acids and metabolism in diabetes and related disorders. -
FXR Agonist
HEC96719 is a selective tricyclic agonist of the farnesoid X receptor (FXR) that demonstrates potent activity with EC50 values of 1.37 nM and 1.55 nM in time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. This compound has shown significant efficacy in improving non-alcoholic steatohepatitis (NASH) and liver fibrosis, exhibiting favorable distribution in liver and intestinal tissues. HEC96719 is valuable for research focusing on non-alcoholic steatohepatitis and related liver conditions. -
FXR Agonist
Cholic acid 3-O-glucuronide disodium is an agonist of the farnesoid X receptor (FXR), exhibiting an EC50 value of 91.5 μM. This compound plays a significant role in the study of bile acid metabolism and detoxification processes. It is a valuable reagent for research applications focused on liver function and metabolic regulation. -
FXR Agonist
FXR agonist 4 is an agonist of the farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. It demonstrates significant efficacy in ameliorating hyperlipidemia, hepatic steatosis, insulin resistance, and hepatic inflammation in dietary-induced obesity (DIO) mouse models. This compound is valuable for research focused on non-alcoholic fatty liver disease (NAFLD) and its associated metabolic disorders. -
FXR Antagonist
β-FXR antagonist 1 is a selective antagonist of the Farnesoid X receptor (FXR), a key regulator of bile acid and lipid metabolism. This compound has demonstrated biological activity in inhibiting FXR-mediated signaling pathways, making it valuable for research focused on metabolic diseases and liver function. Its application spans studies on cholesterol homeostasis, insulin sensitivity, and potential therapeutic interventions in conditions such as non-alcoholic fatty liver disease (NAFLD). -
FXR Agonist
BMS-986318 is a potent non-bile acid agonist of the farnesoid X receptor (FXR), exhibiting EC50 values of 53 nM and 350 nM in FXR Gal4 and SRC-1 recruitment assays, respectively. This compound possesses a favorable ADME profile and has demonstrated efficacy in preclinical models of liver cholestasis and fibrosis, particularly in mouse bile duct ligation studies. BMS-986318 is suitable for research related to nonalcoholic steatohepatitis and its potential therapeutic implications. -
FXR Activator
NR1H4 activator 1 is a highly selective agonist of the Farnesoid X Receptor (FXR), demonstrating exceptional FXR activation with an EC50 value of 1 nM in human assays. This compound has been identified for its potential therapeutic applications in gastrointestinal diseases. Its potent activity makes it a valuable tool for research focused on metabolic regulation and liver health. -
FXR Agonist
Danifexor is a selective agonist of the farnesoid X receptor (FXR), which plays a crucial role in regulating bile acid, lipid, and glucose metabolism. Its activation of FXR is associated with beneficial effects on metabolic disorders and liver diseases. Danifexor is utilized in research exploring therapeutic avenues for conditions such as non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia. -
Fxr Agonist
Hedragonic acid is an oleane-type triterpenoid that acts as a potent agonist for the farnesoid X receptor (FXR). This compound has demonstrated protective effects against liver damage induced by acetaminophen overdose and is effective in reducing liver inflammation. Hedragonic acid is valuable for research focused on liver health, metabolic disorders, and the modulation of bile acid homeostasis. -
FXR Agonist
FXR Agonist 12 is a selective agonist for the farnesoid X receptor (FXR). It effectively down-regulates genes associated with bile acid synthesis while up-regulating those involved in bile acid transport in HepG2 cells. In preclinical studies, FXR Agonist 12 has demonstrated the capability to improve cholestasis induced by ANIT and to mitigate liver damage and fibrosis in mouse models of non-alcoholic steatohepatitis (NASH). This compound is instrumental for research focusing on liver disorders and bile acid metabolism. -
FXR Agonist
Alismanol M is a farnesoid X receptor (FXR) agonist, exhibiting an EC50 value of 50.25 μM. This protostane-type triterpenoid, derived from the rhizome of Alisma orientale, plays a significant role in modulating bile acid homeostasis. Alismanol M is valuable for research into cholestasis and nonalcoholic steatohepatitis, providing insights into liver metabolism and disease mechanisms. -
FXR Agonist
LZ-007 is a highly selective agonist of the farnesoid X receptor (FXR), exhibiting an EC50 of 51 nM in TR-FRET assays and 76 nM in HepG2 cells. This compound demonstrates favorable pharmacokinetic properties in SD rats. LZ-007 has shown efficacy in ameliorating metabolic dysfunction associated with steatohepatitis in models of western diet and CCl4-induced mice, making it a valuable tool for research in metabolic diseases and liver dysfunction. -
FXR Agonist
XJ02862-S2 is a potent agonist of the farnesoid X receptor (FXR). It demonstrates significant biological activity and holds promise as a lead compound in research focused on non-alcoholic fatty liver disease (NAFLD). XJ02862-S2 may serve as a valuable tool for elucidating the role of FXR in metabolic disorders and developing therapeutic strategies for liver-related diseases. -
FXR Agonist
Ferolin is an agonist of the farnesoid X receptor (FXR), exhibiting an EC50 of 0.56 µM. This compound effectively inhibits the expression of pro-inflammatory genes, including iNOS, IL-1β, and TNFα, upon FXR activation. Ferolin is valuable for research focused on metabolic regulation, inflammation, and related therapeutic pathways. -
FXR Antagonist
FXR Antagonist 2 is a diarylamide derivative that serves as a moderate antagonist of the farnesoid X receptor (FXR). This compound demonstrates potential in the investigation of metabolic disorders, specifically hyperlipidemia and type 2 diabetes. Its ability to modulate FXR activity makes it a valuable tool for exploring therapeutic strategies targeting these conditions. -
FXR
GSK8062 is a potent agonist of the farnesoid X receptor (FXR), involved in the regulation of bile acid and lipid metabolism. This compound has demonstrated significant biological activity, including the reduction of weight gain and serum glucose levels in preclinical studies. GSK8062 is valuable for research applications related to metabolic disorders and the therapeutic exploration of liver diseases. -
FXR Agonist
2-Oxokolavenol is a selective agonist of the farnesoid X receptor (FXR), demonstrating an EC50 of approximately 3.7 μM. This compound mitigates acetaminophen-induced hepatocyte damage through an FXR-dependent mechanism, facilitating the recruitment of co-activators and enhancing FXR transcriptional activity. Derived from the plant Aglaia spectabilis, 2-Oxokolavenol is valuable for research on liver diseases and the underlying mechanisms of FXR signaling. -
FXR Agonist
FXR agonist 14 is a selective, orally bioavailable agonist of the farnesoid X receptor (FXR), exhibiting an EC50 of 0.67 nM. This compound demonstrates significant biological activity by alleviating pathological features associated with metabolic syndrome in high-fat and high-sugar diet-induced MASH mice. Additionally, FXR agonist 14 plays a crucial role in exerting protective effects against anti-cholestatic liver disease, making it valuable for research in liver and metabolic disorders. -
FXR Agonist
Fargesone A is a selective agonist of the farnesoid X receptor (FXR). It demonstrates significant anti-inflammatory activity, making it a valuable tool for research in metabolic diseases and inflammatory conditions. This compound is ideal for studies investigating FXR's role in regulating lipid metabolism and inflammation. -
FXR Agonist
FXR Agonist 11 is a selective agonist of the farnesoid X receptor (FXR) with an EC50 of 1.2 μM and a maximum biological effect of 73.7%. This compound significantly elevates glutathione (GSH) levels in liver tissues, making it a valuable tool for investigating mechanisms of drug-induced liver injury and related hepatic disorders. Research applications include studies of metabolic regulation, liver protection, and the modulation of hepatic stress responses. -
FXR Agonist
PX20350 is an FXR (Farnesoid X receptor) agonist, exhibiting EC50 values of 83 nM and 10 nM for mouse and human FXR, respectively. This compound significantly induces the expression of NDRG2 mRNA and demonstrates potent anti-tumor activity by inhibiting the growth and metastasis of liver tumor cells, specifically SK-GI-18. Additionally, PX20350 has been shown to possess anti-tumorigenic effects in orthotopic xenograft mouse models, making it valuable for investigating liver cancer biology and therapeutic strategies. -
FXR Agonist
(E)-GW 4064 is a potent agonist of the farnesoid X receptor (FXR), a nuclear receptor that plays a crucial role in lipid and glucose metabolism. This compound has demonstrated significant biological activity in regulating bile acid synthesis and glucose homeostasis, making it a valuable tool for investigating metabolic disorders. Research applications include studying the effects of FXR activation on metabolic pathways and exploring its potential therapeutic benefits in conditions such as obesity and diabetes. -
FXR Agonist
Fexarine is a potent, non-steroidal selective agonist of the farnesoid X receptor (FXR) with an EC50 of 38 nM. This compound plays a significant role in the regulation of cholesterol and bile acid metabolism. Fexarine is valuable for research applications focusing on metabolic disorders and diseases associated with dysregulated lipid homeostasis. -
CES2 inhibitor; FXR agonist;
FXR/CES2 modulator 1 is a dual modulator that functions as an FXR agonist and a CES2 inhibitor. This compound demonstrates significant potential in reducing the intestinal toxicity associated with irinotecan administration. Its unique mechanism of action makes it a valuable tool for research aimed at understanding FXR modulation and its implications in gastrointestinal safety during chemotherapy. -
FXR-LIFR Modulator
BAR-2227 is a modulator that targets the Farnesoid X Receptor (FXR) as an agonist and inhibits the leukemia inhibitory factor receptor (LIFR). This compound plays a significant role in the investigation of liver fibrosis and associated inflammatory responses. Researchers can utilize BAR-2227 to explore its therapeutic potential in liver diseases and further elucidate underlying mechanisms of fibrosis and inflammation. -
FXR Agonist
Nelumol A is a potent agonist of the farnesoid X receptor (FXR). It is known to regulate bile acid homeostasis, lipid metabolism, and inflammatory responses. Due to its role in metabolic processes, Nelumol A is employed in research studying metabolic disorders, liver diseases, and the pharmacological modulation of FXR pathways. -
FXR Agonist
FXR Agonist 16 is a potent FXR agonist with an EC50 of 2.2 μM, effectively activating FXR transcriptional activity. This compound upregulates small heterodimer partner (SHP) and bile salt export pump (BSEP) while downregulating cytochrome P450 7A1 (Cyp7a1), which contributes to its hepatoprotective properties. FXR Agonist 16 is valuable for research focused on liver injury, demonstrating a reduction in serum AST and ALT levels in models of free fatty acid-induced hepatocellular damage. -
FXR Agonist
FXR Agonist 15 is a potent and selective farnesoid X receptor (FXR) agonist with an EC50 of 0.76 μM. This compound shows high specificity, exhibiting minimal activation of other nuclear receptors such as LXRα/β, PXR, PPARα/β/γ, and THR-β, with EC50 values greater than 10 μM. FXR Agonist 15 demonstrates the ability to mitigate steatosis, lobular inflammation, hepatocyte ballooning, and liver fibrosis, making it a valuable tool for research into nonalcoholic steatohepatitis (NASH). -
FXR Agonist
Fexarene is a potent and selective nonsteroidal agonist of the Farnesoid X Receptor (FXR), exhibiting an EC50 of 36 nM. This compound plays a crucial role in the regulation of cholesterol and bile acid metabolism, making it valuable for research investigating metabolic disorders and liver function. Fexarene's ability to selectively activate FXR positions it as a significant tool for studying its downstream effects in various biological systems. -
Herbicide Safener
Benoxacor is a herbicide safener that primarily acts as a regulator of xenobiotic metabolism. It protects maize from metolachlor toxicity by inducing detoxifying enzymes, such as Glutathione S-transferase, while also activating nuclear receptors like FXR, PXR, and ERRα, and inhibiting aromatase. Research indicates that Benoxacor may exhibit subacute oral toxicity and has been associated with hepatotoxicity in animal models, leading to effects on organ weights and alterations in gut microbiota. This compound is relevant for studies on hepatic steatosis, infertility, breast cancer, and developmental toxicity. -
FXR Agonist
ST-1892 is a potent agonist of the farnesoid X receptor (FXR), exhibiting an EC50 value of 7.2 nM. This compound plays a crucial role in studying metabolic inflammation-related diseases and disorders. Its selective activation of FXR allows for exploration of therapeutic strategies targeting metabolic pathways and liver-related conditions.
